📈 Revenue History (16 Quarters)
🧮 VYGR Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For VYGR, the trailing twelve month revenue is $34.5M.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
VYGR's revenue growth rate of 65.15% (based on log-linear regression of 16 quarters) indicates strong growth, typical of high-growth companies.
Revenue vs Profitability Metrics
Free Cash Flow: $-129.9M →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: $-129.9M →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $-1.81 →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $-107.7M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
VYGR's P/S ratio of 6.2x means investors pay $6.22 for every $1 of annual revenue. A P/S between 3-10 suggests investors expect continued growth and margin expansion.
Gross Margin: Revenue Quality
Gross margin of N/A shows how much of VYGR's revenue remains after direct costs.
Summary: VYGR Revenue Trend
Voyager Therapeutics, Inc. (VYGR) generated $34.5M in trailing twelve-month revenue, growing at 65.15% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. Gross margin: N/A. For complete financial analysis, view the full VYGR stock report on Zyberno.
Frequently Asked Questions
What is VYGR's current revenue?
Voyager Therapeutics, Inc.'s trailing twelve month (TTM) revenue is $34.5M, growing at 65.15% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses.
Is VYGR's revenue growing?
Voyager Therapeutics, Inc. (VYGR) generated $34.5M in trailing twelve-month revenue, growing at 65.15% annually — significantly above the 20% threshold Zyberno associates with high-growth businesses. Gross margin: N/A.
What is VYGR's gross margin?
VYGR's gross margin is N/A.
What is VYGR's Price/Sales ratio?
VYGR's P/S ratio is 6.2x, meaning the market values the company at 6.2 times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. VYGR's revenue is $34.5M with a net income of $-107.7M, showing a net profit margin of -312.6%.
📊 Full VYGR Stock Report →
See VYGR's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 VYGR Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 VYGR Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 VYGR Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 VYGR Earnings Surprise (SUE) →
See whether VYGR is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 VYGR Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 VYGR Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 VYGR Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 VYGR Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.